Procarta

Therapeutics
Share

Procarta Biosystems Ltd is developing an innovative new class of oligonucleotide antimicrobial agent to target bacteria causing serious and life-threatening infection.

Procarta’s innovative DNA-based approach is based on a rationally selected drug-development platform that can rapidly generate new therapeutic agents with a pre-determined spectrum of activity to deliver broad, mid or narrow spectrum agents. Our technology combines a pan-bacterial delivery agent with proprietary specific DNA-based antimicrobials that block expression of key bacterial genes.

Procarta’s proprietary platform can provide multiple products for areas of high unmet medical need and we aim to build a company around providing treatment for patients in critical care situations.

Procarta is supported by a UK Innovation and Science Seed fund, Wren Capital, Meltwind and Development Bank Wales.

PROCARTA ANNOUNCES CARB-X FUNDING AWARD OF UP TO USD 9.2 MILLION TO FIGHT DRUG-RESISTANT PATHOGENS procartabio.com/news/procarta-…

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.